Erica Hobson
Acute Care · Irvine, CANPI 1124652805
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 416 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,234 and has fallen 98.8% since, to $40 in 2025. Among acute care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 416 payments — averaging $22.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$832
- AstraZeneca$616
- E.r. Squibb & Sons, L.L.C.$577
- Pfizer$508
- Merck$472
- Incyte Corporation$466
- plus $6K from 54 others
What the payments were for
- Food & beverage$9,28298%
- Education$1852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,467 in reported general payments places this provider in the 95th percentile of 1,153 acute care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 20 | $536,496 |
| TagrissoOsimertinib Mesylate | 24 | $426,802 |
| IbrancePalbociclib | 19 | $324,698 |
| BrukinsaZanubrutinib | 20 | $302,220 |
| EliquisApixaban | 76 | $78,134 |
| XareltoRivaroxaban | 19 | $27,338 |
| Hydroxyurea | 38 | $1,112 |
| Letrozole | 45 | $1,087 |
| Anastrozole | 40 | $622 |
| Hydrocortisone | 22 | $334 |
| Ondansetron Hcl | 20 | $202 |
| Dexamethasone | 11 | $191 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $191 |
| Gabapentin | 21 | $188 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $466 | $536,49620 claims |
| AstraZenecaTagrisso | $616 | $426,80224 claims |
| PfizerIbrance, Eliquis | $508 | $402,83395 claims |
| Beigene USA, Inc.Brukinsa | $339 | $302,22020 claims |
| Johnson & JohnsonXarelto | $249 | $27,33819 claims |
| Lilly USA, LLCOlanzapine | $133 | $13313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,153 acute care providers in California.
Other acute care in Irvine
- Mary AhmadianIrvine$6K
- Leslie PetersenCamarillo$370K
- Joyce KhremianSan Dimas$73K
- Eleanor VierraSacramento$64K
- Frances DyLos Angeles$57K
- Savannah HarrisVentura$56K
- Kori Ann JohnstonLos Angeles$42K
- Caroline KwongOrange$42K
- Gregory KnutzenColton$41K
- Sunita BoparaiLos Angeles$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.